Today, St. Jude Medical, soon to be part of Abbott, is releasing in Europe its SyncAV CRT software for cardiac resynchronization therapy (CRT) implants and announcing CE Mark approval for the Quadra Assura MP CRT-Defibrillator for use under MRI. The company promises that the new algorithm powering SyncAV CRT will help more patients respond better to CRT devices, while those that would already benefit from existing devices would also receive improvement in therapy.
The Quadra Assura MP features St. Jude’s MultiPoint Pacing technology that utilizes four independent electrodes within the compatible Quartet Quadripolar LV lead to deliver electric signals that best match the natural rhythm of the heart. The new SyncAV CRT software optimizes the delivery of these signals to get a reaction from cardiac tissue that would otherwise may not be forthcoming.
“Although we have made substantial improvements in how we treat heart failure patients, there are still certain patients who are not getting the outcomes with traditional CRT that we would like to see. The SyncAV CRT algorithm dynamically individualizes programming to work towards providing patients with the right settings at the right time helping offer the best possible outcome for even our most complex patients,” in a released statement said Dr. Timothy Betts, consultant cardiologist and electrophysiologist at the Oxford Heart Centre of John Radcliffe Hospital. “Our goal is to utilize the technology to improve outcomes while offering patients who do not respond to therapy with additional options for treatment.”
Source: St. Jude Medical…